Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Amgen ( (AMGN) ) has provided an update.
At its annual meeting held on May 19, 2026, Amgen stockholders re-elected all 12 director nominees to one-year terms, maintaining continuity in board leadership and governance. Shareholders also approved on an advisory basis the company’s executive compensation program, signaling continued investor support for current pay practices.
Investors ratified Ernst & Young LLP as Amgen’s independent registered public accountants for the fiscal year ending December 31, 2026, reinforcing stability in the company’s audit oversight. A shareholder proposal to require an independent board chair failed, preserving the existing board leadership structure and suggesting investors are comfortable with the current governance framework.
The most recent analyst rating on (AMGN) stock is a Buy with a $427.00 price target. To see the full list of analyst forecasts on Amgen stock, see the AMGN Stock Forecast page.
Spark’s Take on AMGN Stock
According to Spark, TipRanks’ AI Analyst, AMGN is a Neutral.
AMGN scores well on core operating fundamentals (strong margins and durable free cash flow) and is supported by a positive earnings-call setup with raised full-year guidance. The overall score is held back primarily by high leverage on the balance sheet and weak technical momentum, while valuation is mixed (P/E 26.1 with a ~3.0% dividend yield).
To see Spark’s full report on AMGN stock, click here.
More about Amgen
Amgen is a global biotechnology company focused on discovering, developing and manufacturing innovative human therapeutics, particularly in areas such as oncology, cardiovascular disease, inflammation and other serious illnesses. The company markets biologic and biosimilar medicines worldwide and targets both specialty and primary care markets, leveraging its research capabilities and large-scale biologics manufacturing infrastructure.
Average Trading Volume: 2,657,636
Technical Sentiment Signal: Buy
Current Market Cap: $175.1B
Find detailed analytics on AMGN stock on TipRanks’ Stock Analysis page.